Pentostatin, cyclophosphamide, and rituximab (PCR) has comparable activity but appears to be better tolerated than fludarabine, cyclophosphamide, and rituximab (FCR) in patients with previously treated chronic lymphocytic leukemia Meeting Abstract

  

Authors:	Lamanna, N.; Kalaycio, M.; Maslak, P.; Heaney, M. L.; Brentjens, R.; Jurcic, J.; Biederman, E.; Gencarelli, A. N.; Panageas, K. S.; Scheinberg, D. A.; Weiss, M. A.
Abstract Title:	Pentostatin, cyclophosphamide, and rituximab (PCR) has comparable activity but appears to be better tolerated than fludarabine, cyclophosphamide, and rituximab (FCR) in patients with previously treated chronic lymphocytic leukemia
Meeting Title:	47th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	106
Issue:	11 Pt. 1
Meeting Dates:	2005 Dec 10-13
Meeting Location:	Atlanta, GA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2005-11-01
Start Page:	601A
End Page:	602A
Language:	English
ACCESSION:	WOS:000233426003489
PROVIDER:	wos
PUBMED:	16342400
DOI:	10.1182/blood.V106.11.2127.2127
Notes:	--- - Meeting Abstract: 2127 - 47th Annual Meeting of the American-Society-of-Hematology - DEC 10-13, 2005 - Atlanta, GA - Part 1 - "Source: Wos"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/44718